Gilead to Present PURPOSE 5 Results in Glasgow, Examining Lenacapavir Persistence and Safety
Key Facts
Gilead plans to present results from the PURPOSE 5 study at HIV Glasgow 2026 in Glasgow, scheduled for November 8 to 11, according to the company. Gilead said the results will address participants’ persistence with and the safety of the two HIV prevention options. That places the announced presentation’s focus on persistence and adverse events, rather than an established comparison of the options’ preventive efficacy. While the company is announcing the results ahead of the conference, the official page reviewed did not include additional numerical details about the trial results. The Glasgow presentation is expected to provide details on PURPOSE 5 as part of the company’s broader conference program.
According to Gilead, its HIV Glasgow program will include results from more than 50 studies, including late-breaking data and two oral presentations. The company places PURPOSE 5 results within this research program, which brings together data from multiple HIV studies. The published announcement does not specify which results will be the focus of the oral presentations, but points to Gilead’s broad participation in the meeting. The conference runs for four days, from November 8 to 11, 2026, in Glasgow, U.K., according to the official program. The conference is therefore the next announced opportunity to obtain the full presentation of the study results.
PURPOSE 5 examines continued use of lenacapavir compared with emtricitabine and tenofovir disoproxil fumarate, known as Truvada, according to the ClinicalTrials.gov record. The record says the study assesses safety, treatment acceptability and pharmacokinetics in people who may benefit from pre-exposure prophylaxis. This description aligns with Gilead’s statement that its results will examine persistence and adverse events among users of the two prevention options. This means the results will cover treatment continuation as well as safety within the comparison set out in the study design. The information cited here from the record provides no numerical comparison outcome or estimate of one option’s efficacy relative to the other.
Gilead says lenacapavir for HIV pre-exposure prophylaxis is approved in the United States, the European Union and several countries worldwide. The Centers for Disease Control and Prevention confirms that the U.S. Food and Drug Administration approved the injection for pre-exposure prophylaxis in June 2025, to be administered every 6 months. In the same year, the World Health Organization recommended offering long-acting lenacapavir, administered twice yearly, as an additional prevention option. The organization’s director-general said trials showed that the drug prevents almost all HIV infections among people at risk. The WHO cited 1.3 million new HIV infections worldwide in 2024 in its statement, placing the recommendation in the context of the need for additional prevention options.
In the earlier PURPOSE 1 trial, Gilead said it recorded no infections in the lenacapavir group and described the study results as showing 100% efficacy. The company’s chief medical officer at the time said that “zero infections and 100% efficacy demonstrated the potential of twice-yearly lenacapavir.” Those figures relate to PURPOSE 1 and its results announcement in 2024, and do not represent the outcome of PURPOSE 5. The PURPOSE 5 results due to be presented in Glasgow address persistence and safety in the study, according to Gilead’s description. Their interpretation therefore depends on the details the presentation provides about participants and the prevention options being compared.
EL7 data showed Gilead shares closed at $167.57 on November 5, 2026. That figure is the closing price for the session and does not include the stock’s trading range during the session. The PURPOSE 5 presentation is scheduled after that close, with the HIV Glasgow conference beginning on November 8. No other data on share price movements or the market’s response to the results announcement were included in the information available here. The study presentation at the conference, along with the company’s announcement of a program featuring more than 50 studies, is the next anticipated event in this story.